Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of givastomig + nivolumab + chemotherapy in CLDN18.2-positive, PD-L1-positive advanced gastroesophageal adenocarcinoma
jRCT2031250820Phase 2Recruiting
- Sponsor
- I-Mab
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of givastomig in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (3 arms), sponsored by I-Mab. Primary endpoints: Progression-free survival (PFS) and Safety of givastomig combination. Started Mar 2026; status: recruiting.
02
Drugs
givastomig
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2031250820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250820.